Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS NYSE:ADCT OTCMKTS:NEVPF OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/AN/AN/AN/AADCTADC Therapeutics$3.40+0.1%$3.80$2.05▼$4.98$431.81M1.831.20 million shs648,483 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$53.34$50.50$37.51▼$60.85$339.80B0.52.60 million shs1.36 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%-90.00%ADCTADC Therapeutics0.00%+4.21%-13.72%-22.75%+40.58%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%0.00%RHHBYRoche0.00%+4.40%+3.29%-11.06%+34.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/AN/AN/AN/AADCTADC Therapeutics$3.40+0.1%$3.80$2.05▼$4.98$431.81M1.831.20 million shs648,483 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/ARHHBYRoche$53.34$50.50$37.51▼$60.85$339.80B0.52.60 million shs1.36 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%-90.00%ADCTADC Therapeutics0.00%+4.21%-13.72%-22.75%+40.58%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%0.00%RHHBYRoche0.00%+4.40%+3.29%-11.06%+34.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AADCTADC Therapeutics 2.50Moderate Buy$8.00135.64% UpsideNEVPFAbliva AB (publ) 0.00N/AN/AN/ARHHBYRoche 2.45Hold$51.50-3.45% DownsideCurrent Analyst Ratings BreakdownLatest RHHBY, NEVPF, ACUS, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/24/2026RHHBYRoche Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$46.004/20/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026RHHBYRoche ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy3/23/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.002/26/2026RHHBYRoche Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AADCTADC Therapeutics$81.36M5.31N/AN/A($1.70) per share-2.00NEVPFAbliva AB (publ)$10K1,128.43N/AN/A$0.02 per share1.40RHHBYRoche$76.45B4.44$3.60 per share14.81$7.18 per share7.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AN/AADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)NEVPFAbliva AB (publ)-$9.01MN/AN/AN/AN/AN/A-117.92%-102.44%N/ARHHBYRoche$15.55BN/AN/A15.204.39N/AN/AN/A7/23/2026 (Estimated)Latest RHHBY, NEVPF, ACUS, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million3/10/2026Q4 2025ADCTADC Therapeutics-$0.32-$0.04+$0.28-$0.04$22.29 million$23.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AADCTADC TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ARHHBYRoche$0.971.82%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACUSAcusphereN/AN/AN/AADCTADC TherapeuticsN/A4.094.02NEVPFAbliva AB (publ)N/A7.997.99RHHBYRoche0.721.381.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AADCTADC Therapeutics41.10%NEVPFAbliva AB (publ)N/ARHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ADCTADC Therapeutics5.40%NEVPFAbliva AB (publ)N/ARHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableNEVPFAbliva AB (publ)8403.01 millionN/ANot OptionableRHHBYRoche103,2496.37 billionN/ANot OptionableRHHBY, NEVPF, ACUS, and ADCT HeadlinesRecent News About These CompaniesAZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors34 minutes ago | zacks.comGenentech highlights new breast cancer and precision oncology data ahead of ASCO 2026 (RHHBY)May 21, 2026 | msn.comEXEL Collaborates With MRK for Late-Stage Colorectal Cancer StudyMay 20, 2026 | zacks.comBAYRY or RHHBY: Which Is the Better Value Stock Right Now?May 20, 2026 | zacks.comGenentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast CancerMay 19, 2026 | businesswire.comRoche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancerMay 19, 2026 | globenewswire.comRoche Holding AG (RHHBY) Analyst/Investor Day TranscriptMay 18, 2026 | seekingalpha.comRoche, Medicines Patent Pool sign deal to expand access to influenza drugMay 18, 2026 | reuters.comRoche's Tecentriq Wins FDA Nod for Label Expansion in Bladder CancerMay 18, 2026 | zacks.comRoche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of "Hold" from BrokeragesMay 16, 2026 | americanbankingnews.comFDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided TreatmentMay 16, 2026 | finance.yahoo.comRoche gets second European approval for Alzheimer's testMay 12, 2026 | reuters.comRoche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)May 12, 2026 | globenewswire.comErste Group Bank Analysts Lift Earnings Estimates for RocheMay 8, 2026 | marketbeat.comF. Hoffmann-La Roche Ltd: Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsMay 7, 2026 | finanznachrichten.deRoche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics ToolsMay 7, 2026 | wsj.comSwitzerland's Roche agrees to acquire US-based PathAIMay 7, 2026 | reuters.comRoche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsMay 7, 2026 | globenewswire.comFY2026 EPS Estimates for Roche Raised by Erste Group BankApril 30, 2026 | marketbeat.comGenentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026April 30, 2026 | businesswire.comRoche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026April 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRHHBY, NEVPF, ACUS, and ADCT Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.ADC Therapeutics NYSE:ADCT$3.40 +0.01 (+0.15%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$3.40 0.00 (0.00%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Abliva AB (publ) OTCMKTS:NEVPF$0.03 0.00 (0.00%) As of 05/22/2026Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Roche OTCMKTS:RHHBY$53.34 0.00 (0.00%) As of 05/22/2026 04:00 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
